BioNTech releases first quarter 2025 financials

5 May 2025

German biotech BioNTech (Nasdaq: BNTX) saw its shares dip 3.4% to $101.44 today, after it reported financial results for the three months ended March 31, 2025 and provided an update on its corporate progress.

The company's revenue slightly decreased to 182.8 million euros ($206.2 million), compared to 187.6 million euros during the same period in 2024. Despite this revenue decline, BioNTech continues to focus on its strategic projects, particularly in oncology and COVID-19 vaccine development.

Net loss for the quarter was 415.8 million euros for the three months, compared to a net loss of 315.1 million euros for the comparative prior year period.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK